The effect of spironolactone on the levels of GATA4 protein and hypoxia inducible factor-1α in patients receiving coronary stent implantation

doi:10.5246/jcps.2022.02.011

Abstract

Abstract:

In the present study, we aimed to explore the protective effect of spironolactone on cardiac function in patients undergoing coronary stent implantation by determining the serum levels of GATA4 and hypoxia-inducible factor-1α (HIF-1α) proteins before and after the coronary stent implantation. A total of 134 patients undergoing coronary stent implantation in our hospital from March 2019 to March 2020 were retrospectively selected using the propensity score matching (PSM) method. Of the 134 patients, 67 patients taking spironolactone were used as a test group, and the other 67 patients without taking spironolactone were used as a control group. In all patients, the levels of serum GATA4, HIF-1α, and troponin I proteins were determined before as well as 24 h and 6 months after the coronary stent implantation. Left ventricular ejection fraction (LVEF) and left ventricular systolic global longitudinal strain (GLS) were determined before and 6 months after the coronary stent implantation. There were no significant differences in the HIF-1α level between the two groups before and 6 months after the operation, while the HIF-1α level was significantly lower in the test group compared with the control group at 24 h after the operation (P < 0.01). There were no significant differences in the GATA4 protein level between the two groups before and 24 h after the operation, while the GATA4 protein level was significantly lower in the test group compared with the control group at 6 months after the operation (P < 0.01). There was no significant difference in LVEF between the two groups before and 6 months after the operation. GLS was significantly improved at 6 months after the operation compared with that before the operation in both groups, while GLS was significantly better in the test group compared with the control group at 6 months after the operation (P < 0.01). Collectively, spironolactone could protect cardiac function probably by improving myocardial hypoxia and inhibiting myocardial remodeling.

Key words: Coronary stent implantation, Spironolactone, Hypoxia-inducible factor-1α, GATA4 protein, Ischemic cardiomyopathy, Global longitudinal strain

Supporting:

Yumei Lou, Xiaoying Ge, Zhelan Zheng, Linyuan Xie, Jiangfang Lian, Wenjun Shen, Kenan Lou, Wanying Hu, Dexing Hu. The effect of spironolactone on the levels of GATA4 protein and hypoxia inducible factor-1α in patients receiving coronary stent implantation[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(2): 134-141.

Figures/Tables 5

Table 1. General data in patients of the two groups.

Table 2. Levels of troponin (μg/L) and HIF-1α (pg/mL) before and after the coronary stent implantation in the two groups.

Table 3. GATA4 protein (ng/L) before and after the coronary stent implantation in the two groups.

Table 4. Comparisons of GLS and LVEF between before and 6 months after the operation in the two groups (%).

References 28

[1]	Yang, L.; Wu, J.J.; Wang, J.; Zheng, H. Effect of HIF-1α on mitochondrial function after sevoflurane postconditioning alleviating ischemia-reperfusion injury in rat. Chin. J. Evid. Base. Cardiovasc. Med. 2020, 12, 304–307.
[2]	Tekin, D.; Dursun, A.D.; Xi, L. Hypoxia inducible factor 1 (HIF-1) and cardioprotection. Acta Pharmacol. Sin. 2010, 31, 1085–1094.
[3]	Zhang, H.Y.; Geng, W. Correlations of serum miR-34a and HIF-1α levels with coronary collateral circulation in the patients with coronary heart disease. Chongqing Med. 2019, 48, 2139–2141, 2155.
[4]	Jiang, L.; Yang, R.Q.; Cheng, X.S. Advances on the treatment of hypoxia inducible factor-1 in ischemic heart disease. Guangdong Med. 2012, 33, 2509–2511.
[5]	Välimäki, M.J.; Ruskoaho, H.J. Targeting GATA4 for cardiac repair. IUBMB Life. 2020, 72, 68–79.
[6]	Yu, W.; Huang, X.; Tian, X.; Zhang, H.; He, L.; Wang, Y.; Nie, Y.; Hu, S.; Lin, Z.; Zhou, B.; Pu, W.; Lui, K.O.; Zhou, B. GATA4 regulates Fgf16 to promote heart repair after injury. Dev. Camb. Engl. 2016, 143, 936–949.
[7]	He, J.G.; Yan, D.; Wang, P.; Li, H.R. Research progress of role of GATA-4 in cardiac injury repair. Med. Recapitu l. 2015, 21, 4033–4036.
[8]	Wu, C.H.; Lin, H.F.; Lin, W.W.; Liu, Y.W.; You, X.; Lin, C.H.; Lin, R.F.; Zeng, D.Y.; Huang, P.F. A prospective cohort study on the relationship between vancomycin steady-state trough concentration and efficacy and safety in Chinese adults. J. Chin. Pharm. Sci. 2020, 29, 341–354.
[9]	Zhang, M.; Zhang, Y.; Yin, L.X. Guidelines for clinical application of echocardiography in the evaluation of cardiac systolic and diastolic function. Chin. J. Ultrason. 2020, 29, 461–477.
[10]	Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; Lancellotti, P.; Muraru, D.; Picard, M.H.; Rietzschel, E.R.; Rudski, L.; Spencer, K.T.; Tsang, W.; Voigt, J.U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J. Am. Soc. Echocardiogr. 2015, 28, 1–39.e14.
[11]	Larik, F.A.; Saeed, A.; Shahzad, D.; Faisal, M.; El-Seedi, H.; Mehfooz, H.; Channar, P.A. Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives. Steroids. 2017, 118, 76–92.
[12]	Dong, Q.; Liu, K.S.; Liu, H.B.; Li, S.R.; Han, Y.P.; Zhang, L.P.; Wang, Y.; Liu, G.; Wang, X.P.; Xu, L.F.; Li, X.C. Effect of spironolactone on left ventricular remodeling in patients with acute myocardial infarction. Chin. J. Cardio. 2005, 33, 315–319.
[13]	Upadhya, B.; Hundley, W.G.; Brubaker, P.H.; Morgan, T.M.; Stewart, K.P.; Kitzman, D.W. Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. J. Am. Geriatr. Soc. 2017, 65, 2374–2382.
[14]	Dong, D.; Fan, T.T.; Ji, Y.S.; Yu, J.Y.; Wu, S.; Zhang, L. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. Int. Urol. Nephrol. 2019, 51, 755–764.
[15]	Safdar, Z.; Frost, A.; Basant, A.; Deswal, A.; O’Brian Smith, E.; Entman, M. Spironolactone in pulmonary arterial hypertension: results of a cross-over study. Pulm. Circ. 2020, 10, 2045.
[16]	Maron, M.S.; Chan, R.H.; Kapur, N.K.; Jaffe, I.Z.; McGraw, A.P.; Kerur, R.; Maron, B.J.; Udelson, J.E. Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy. Am. J. Med. 2018, 131, 837–841.
[17]	Papademetriou, V.; Toumpourleka, M.; Imprialos, K.P.; Alataki, S.; Manafis, A.; Stavropoulos, K. The role of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction. Curr. Pharm. Des. 2018, 24, 5517–5524.
[18]	Jiang, Y.R. Efficacy and safety of spironolactone in mono-therapy versus low does spironolactone in combined-therapy for the treatment of idiopathic hyperaldosteronism. China Med. Abstr. (Intern. Med). 2018, 35, 147.
[19]	Manolis, A.A.; Manolis, T.A.; Melita, H.; Manolis, A.S. Eplerenone versus spironolactone in resistant hypertension: an efficacy and/or cost or just a men’s issue? Curr. Hypertens. Rep. 2019, 21, 1–14.
[20]	Serenelli, M.; Jackson, A.; Dewan, P.; Jhund, P.S.; Petrie, M.C.; Rossignol, P.; Campo, G.; Pitt, B.; Zannad, F.; Ferreira, J.P.; McMurray, J.J.V. Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Fail. 2020, 8, 188–198.
[21]	Ong, S.G.; Lee, W.H.; Theodorou, L.; Kodo, K.; Lim, S.Y.; Shukla, D.H.; Briston, T.; Kiriakidis, S.; Ashcroft, M.; Davidson, S.M.; Maxwell, P.H.; Yellon, D.M.; Hausenloy, D.J. HIF-1 reduces ischaemia-reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovasc. Res. 2014, 104, 24–36.
[22]	Yang, L.; Ma, N.; Wu, J.J.; Yu, J.; Ye, J.R.; Wang, J.; Zheng, H. Role of HIF-1α/BNIP3 signaling pathway in sevoflurane-induced attenuation of myocardial ischemia-reperfusion injury in rats: relationship with autophagy. Chin. J. Anesthesi. 2020, 40, 99–102.
[23]	de Mignot, A.; Donal, E.; Zaroui, A.; Reant, P.; Salem, A.; Hamon, C.; Monzy, S.; Roudaut, R.; Habib, G.; Lafitte, S. Global longitudinal strain as a major predictor of cardiac events in patients with depressed left ventricular function: a multicenter study. J. Am. Soc. Echocardiogr. 2010, 23, 1019–1024.
[24]	Di Salvo, G.; Rea, A.; Mormile, A.; Limongelli, G.; D’Andrea, A.; Pergola, V.; Pacileo, G.; Caso, P.; Calabrò, R.; Russo, M.G. Usefulness of bidimensional strain imaging for predicting outcome in asymptomatic patients aged ≤ 16 years with isolated moderate to severe aortic regurgitation. Am. J. Cardiol. 2012, 110, 1051–1055.
[25]	Witkowski, T.G.; Thomas, J.D.; Debonnaire, P.J.M.R.; Delgado, V.; Hoke, U.; Ewe, S.H.; Versteegh, M.I.M.; Holman, E.R.; Schalij, M.J.; Bax, J.J.; Klautz, R.J.M.; Marsan, N.A. Global longitudinal strain predicts left ventricular dysfunction after mitral valve repair. Eur. Heart J. Cardiovasc. Imaging. 2013, 14, 69–76.
[26]	Wu, Y.H.; Deng, Y.B.; Shentu, W.H.; Xiong, L.; Zhao, C.Y.; Zhu, Y.; Huang, Y.Q. Two-dimensional strain in patients with coronary artery disease measured by speckle tracking echocardiography. Chin. J. Ultrason. 2008, 17, 745–748.
[27]	Sun, S.; Li, T.; Jin, L.; Piao, Z.H.; Liu, B.; Ryu, Y.; Choi, S.Y.; Kim, G.R.; Jeong, J.E.; Wi, A.J.; Lee, S.J.; Kee, H.J.; Jeong, M.H. Dendropanax morbifera prevents cardiomyocyte hypertrophy by inhibiting the Sp1/GATA4 pathway. Am. J. Chin. Med. 2018, 46, 1021–1044.
[28]	Maliken, B.D.; Kanisicak, O.; Karch, J.; Khalil, H.; Fu, X.; Boyer, J.G.; Prasad, V.; Zheng, Y.; Molkentin, J.D. Gata4-dependent differentiation of c-kit⁺ –derived endothelial cells underlies artefactual cardiomyocyte regeneration in the heart. Circulation. 2018, 138, 1012–1024.